MergerMay 4, 2026, 08:01 AM
Rallybio Merger with Candid Terminated; Receives $50M Fee
AI Summary
Rallybio Corporation announced the termination of its merger agreement with Candid Therapeutics, Inc. on May 3, 2026. Candid terminated the agreement to enter into an alternative agreement with UCB S.A. As a result, Rallybio is entitled to receive a $50,000,000 Parent Termination Fee and an additional $375,000 for expense reimbursement. Rallybio has waived certain rights and agreed to release claims upon receipt of these payments, and plans to withdraw its Form S-4 registration statement.
Key Highlights
- Rallybio's merger agreement with Candid Therapeutics terminated on May 3, 2026.
- Candid terminated the merger to pursue an alternative agreement with UCB S.A.
- Rallybio is entitled to receive a $50,000,000 Parent Termination Fee.
- Rallybio will also receive $375,000 for expense reimbursement.
- Rallybio waived certain rights and agreed to release claims upon payment.
- Rallybio intends to withdraw its Form S-4 registration statement.